

Table 15.13
Immunosuppression Use for Maintenance by Regimen
Two Years Following Transplantation, 1999 to 2007
Recipients with Heart Transplants

	Transplant Year								
	1999	2000	2001	2002	2003	2004	2005	2006	2007
Transplants	2,188	2,199	2,202	2,155	2,057	2,015	2,125	2,193	2,209
Functioning Graft at 2 Years PostTx	1,670	1,729	1,748	1,715	1,658	1,645	1,718	1,783	1,819
With Maintenance Use Recorded at 2 Years PostTx	1,605	1,706	1,704	1,661	1,648	1,624	1,541	1,528	1,582
CyA	2.1%	1.8%	1.2%	1.0%	1.0%	0.7%	0.1%	0.5%	0.5%
Tac	1.8%	2.1%	2.0%	2.0%	1.6%	2.8%	3.2%	3.7%	4.2%
--- + MMF/MPA	0.1%	0.1%	0.2%	0.2%	0.3%	0.2%	0.0%	0.3%	0.1%
CyA + MMF/MPA	12.3%	14.1%	12.9%	11.4%	12.0%	10.8%	10.6%	9.9%	9.0%
Tac + MMF/MPA	5.2%	7.2%	12.2%	11.2%	15.8%	18.9%	21.9%	24.0%	28.0%
--- + OtherAntimet	0.1%	0.1%	0.1%	0.0%	0.0%	0.1%	0.0%	0.0%	0.1%
CyA + OtherAntimet	3.9%	3.2%	2.1%	2.0%	1.3%	1.6%	1.1%	1.4%	0.8%
Tac + OtherAntimet	1.7%	1.1%	1.5%	1.6%	1.5%	1.4%	2.1%	1.8%	2.6%
--- + MMF/MPA + OtherAntimet	0.0%	0.0%	0.1%	0.0%	0.0%	0.1%	0.0%	0.0%	0.0%
CyA + MMF/MPA + OtherAntimet	0.0%	0.0%	0.0%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%
Tac + MMF/MPA + OtherAntimet	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.1%	0.0%
--- + Siro/Evero	0.1%	0.0%	0.1%	0.0%	0.1%	0.0%	0.0%	0.1%	0.1%
CyA + Siro/Evero	0.2%	0.6%	0.4%	1.7%	1.5%	0.9%	0.5%	1.2%	1.2%
Tac + Siro/Evero	0.2%	0.4%	1.2%	2.7%	2.5%	2.2%	2.5%	2.1%	2.3%
--- + MMF/MPA + Siro/Evero	0.0%	0.1%	0.2%	0.3%	0.4%	0.7%	1.6%	1.4%	1.3%
CyA + MMF/MPA + Siro/Evero	0.1%	0.1%	0.4%	0.4%	0.4%	0.3%	0.3%	0.3%	0.0%
Tac + MMF/MPA + Siro/Evero	0.0%	0.2%	0.1%	0.3%	0.4%	0.7%	0.5%	0.7%	0.8%
--- + OtherAntimet + Siro/Evero	0.0%	0.1%	0.1%	0.1%	0.1%	0.2%	0.1%	0.2%	0.1%
CyA + OtherAntimet + Siro/Evero	0.1%	0.1%	0.1%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%
Tac + OtherAntimet + Siro/Evero	0.0%	0.0%	0.0%	0.2%	0.0%	0.0%	0.0%	0.1%	0.0%
--- + Steroids	0.5%	0.1%	0.4%	0.3%	0.2%	0.2%	0.1%	0.1%	0.0%
CyA + Steroids	5.4%	2.1%	1.7%	1.4%	1.4%	0.8%	1.0%	0.7%	1.2%
Tac + Steroids	2.8%	2.8%	3.4%	3.0%	3.4%	3.3%	3.3%	2.5%	2.8%
--- + MMF/MPA + Steroids	0.2%	0.2%	0.9%	0.5%	0.2%	0.2%	0.3%	0.1%	0.1%
CyA + MMF/MPA + Steroids	29.9%	30.9%	25.9%	20.8%	18.9%	15.8%	15.0%	13.6%	11.5%
Tac + MMF/MPA + Steroids	14.5%	17.6%	20.0%	20.5%	21.4%	23.6%	24.5%	24.3%	23.8%
--- + OtherAntimet + Steroids	0.1%	0.1%	0.0%	0.1%	0.1%	0.0%	0.0%	0.0%	0.0%
CyA + OtherAntimet + Steroids	9.0%	5.7%	3.0%	2.9%	1.3%	1.7%	0.6%	0.7%	0.3%
Tac + OtherAntimet + Steroids	2.8%	2.8%	1.8%	2.0%	2.0%	1.6%	1.4%	1.8%	2.2%
--- + Siro/Evero + Steroids	0.2%	0.3%	0.5%	0.6%	0.7%	0.3%	0.3%	0.4%	0.1%
CyA + Siro/Evero + Steroids	1.1%	1.3%	0.8%	1.3%	2.1%	1.2%	1.0%	1.9%	2.1%
Tac + Siro/Evero + Steroids	1.0%	2.1%	3.4%	4.5%	4.1%	2.2%	2.5%	2.0%	1.3%
Other Regimen	4.7%	3.1%	3.4%	6.7%	5.6%	7.5%	5.4%	4.1%	3.6%

Source: OPTN/SRTR Data as of October 1, 2010.

Notes:

Percentages are calculated based on the total number of patients with maintenance use at two years following transplantation. They sum to 100 percent for each column.

---: No Calcineurin Inhibitor Use; CyA: Cyclosporine; Tac: Tacrolimus.

MMF: Mycophenolate Mofetil; MPA: Mycophenolate Sodium; Siro: Sirolimus; Evero: Everolimus; OtherAntimet: Antimetabolites excluding MMF and MPA.

"Other Regimen" includes drug combinations that are different from the listed regimens and drugs from the text field entering.